Publication at First Faculty of Medicine |
2019
Abstract
In 2018, the American Diabetes Association (ADA) updated the recommendations for diabetes treatment in collaboration with the European Diabetes Society (EASD). Non-pharmacological measures remain important and metformin remains the drug of rst choice.
Inadequate diabetes compensation should be intensied in time; when choosing follow-up therapy, we take into account patient's co-morbidity or the economic aspects of treatment. This amendment is outlined in a schematic diagram on page 6 and discussed in more detail below.